Correction to: The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparison.
更正:ERA Registry 2022 年度報告:歐洲腎臟替代治療流行病學,聚焦性別比較
Clin Kidney J 2025-05-07
Correction to: Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
修正:在接受 agalsidase beta 治療的 Fabry 病患者中,腎功能下降及嚴重臨床事件風險的減少:來自 Fabry 註冊的匹配分析。
Clin Kidney J 2024-10-18
The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparisons.
ERA 登記年報 2022:歐洲腎臟替代療法的流行病學,重點關注性別比較。
Clin Kidney J 2025-02-26
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事:「WCN25-3808 末期腎臟病(ESRD)中的非酒精性脂肪肝病(NAFLD)—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月,第10卷,第2期,增刊,S339-S340頁]
Kidney Int Rep 2025-04-30
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226].
更正啟事:「ALIGN 隨機對照研究 Atrasentan 用於 IgA Nephropathy 患者之研究設計與基線特徵」[第10卷,第1期,2025年1月,頁217-226]
Kidney Int Rep 2025-04-30
重點摘要:
這則通知是用來更正 DOI 為 10.1016/j.ekir.2024.10.004 的文章。內容很可能是針對該篇發表的錯誤進行修正,或是提供相關的最新更新。
PubMedDOI
Corrigendum to "PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY" [Volume 10, Issue 3, March 2025, Pages 645-649].
「PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY」[第10卷,第3期,2025年3月,第645-649頁]之更正啟事
Kidney Int Rep 2025-06-09
Corrigendum to "Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand" [Volume 10, Issue 3, March 2025, Pages 762-771].
「更正啟事:Aotearoa New Zealand 活體腎臟捐贈者於捐腎手術後之預後分析」【第10卷,第3期,2025年3月,頁762-771】
Kidney Int Rep 2025-06-09
Corrigendum to "SAT-040 RENAL SAFETY OF DIRECT ACTING ANTIVIRAL DRUGS IN POST LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION" [Volume 5, Issue 3, Supplement, March 2020, Pages S18-S19].
「SAT-040 直接作用型抗病毒藥物於肝臟移植後慢性 C 型肝炎患者之腎臟安全性」更正啟事 [第5卷,第3期,增刊,2020年3月,S18-S19頁]
Kidney Int Rep 2025-06-09
Correction to: The benefit of reduced serum phosphate levels depends on patient characteristics: a nationwide cohort study.
更正:降低血清磷酸鹽濃度的益處取決於病人特徵:全國性世代研究
Clin Kidney J 2025-06-11
Correction to: Recognition of intraglomerular histological features with deep learning in protocol transplant biopsies and their association with kidney function and prognosis.
更正:利用深度學習辨識腎臟移植活檢中腎小球內組織學特徵及其與腎功能和預後的關聯
Clin Kidney J 2025-06-26
Correction to: The management of chronic kidney disease in primary care in Denmark: patient characteristics, treatment, follow-up, progression and referral.
更正:丹麥基層醫療中慢性腎臟病的管理:病人特徵、治療、追蹤、進展與轉診
Clin Kidney J 2025-07-02